Bloomberg BNA’s Corporate Law & Accountability Report is available on the Corporate Law Resource Center. This news service keeps corporate practitioners informed of legal developments of...
May 19 — An investor has sued Perrigo Co., alleging the over-the-counter drugmaker violated federal securities laws by misrepresenting the strength of its business while trying to convince shareholders to reject Mylan NV's takeover bid late last year.
Perrigo and former chief executive officer Joseph Papa made false and misleading statements, including that the Mylan offer was inadequate, Roofers' Pension Fund said in a would-be class action filed May 18 at the U.S. District Court for the District of New Jersey.
The misstatements ultimately caused a majority of shareholders to reject Mylan's $26 billion offer, the investor said.
A Perrigo representative declined to comment on the lawsuit.
Papa left Perrigo in April to become the new CEO of Valeant Pharmaceuticals International Inc.
Mylan had offered $75 in cash and 2.3 Mylan shares for each Perrigo share. The companies engaged in a war of words over Mylan's repeated offers, at one point counter-suing each other in federal court over alleged misstatements (59 CARE 59, 11/2/15).
In November 2015, Mylan's tender offer was rejected by a majority of Perrigo shareholders (68 CARE, 11/16/15).
According to the complaint, Perrigo and Papa made materially misleading statements and omissions and “engaged in a scheme to deceive the market” in order to defend against Mylan's proposal. The investor claimed the misrepresentations were disclosed when Perrigo reported lower-than-expected earnings in February, and announced a first-quarter net loss of $0.93 per share earlier this month, after which the company's stock price fell steeply.
To contact the reporter on this story: Michael Greene in Washington at email@example.com
To contact the editor responsible for this story: Yin Wilczek at firstname.lastname@example.org
The complaint is available at http://www.bloomberglaw.com/public/document/ROOFERS_PENSION_FUND_v_PAPA_et_al_Docket_No_216cv02805_DNJ_May_18/1.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)